drugset
Drugs / MARDEPODECT
last change Feb 2017 re-read 2 minutes ago

MARDEPODECT

also known as Pf-02545920 · MP-10 · PF-2545920

Small molecule targets PDE10A

Developed for
schizophrenia · Huntington disease · schizoaffective disorder
Investigated by
Pfizer · Yale University

Trials 10 · a red edge is where a trial was stopped

today NCT02342548 · Ph 2 NCT02197130 · Ph 2 NCT01918202 · Ph 1 NCT01939548 · Ph 2 NCT01806896 · Ph 2 NCT01829048 · Ph 1 NCT01244880 · Ph 1 NCT01175135 · Ph 2 NCT01103726 · Ph 1 NCT00463372 · Ph 1
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 15 trials
Phase 1 NCT01918202 Mar → Sep 2014 — Pfizer Completed No outcome recorded
Phase 1 NCT01829048 Mar → Oct 2013 schizophrenia Pfizer Completed No outcome recorded
Phase 1 NCT01244880 Apr 2011 → Aug 2012 — Pfizer Terminated No outcome recorded
Phase 1 NCT01103726 May 2010 → Nov 2011 — Pfizer Completed No outcome recorded
Phase 1 NCT00463372 Oct 2006 → May 2007 schizoaffective disorder, schizophrenia Pfizer Completed No outcome recorded
Phase 25 trials
Phase 2 NCT02342548 Feb 2015 → Feb 2017 Huntington disease Pfizer Terminated No outcome recorded
Phase 2 NCT02197130 Sep 2014 → Sep 2016 Huntington disease Pfizer Completed No outcome recorded
Phase 2 NCT01939548 Oct 2013 → Oct 2014 schizophrenia Pfizer Terminated No outcome recorded
Phase 2 NCT01806896 Sep 2013 → Jan 2015 Huntington disease Pfizer Completed No outcome recorded
Phase 2 NCT01175135 Oct 2010 → Aug 2011 schizophrenia Pfizer Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00570063 Comparator Nov 2007 → Feb 2008 schizophrenia Pfizer Terminated No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 13 sources stand behind the page.

FieldValueCited text
Known as MARDEPODECT ChEMBL registry synonym — accepted as the source's own label CHEMBL562318 ↗
Known as MP-10 ChEMBL registry synonym — accepted as the source's own label CHEMBL562318 ↗
Known as Pf-02545920 “A Phase 2, Double-blind Randomized, Sequential Treatment Group, Placebo-controlled Study To Evaluate The Safety, Tolerability And Brain Cortico-striatal Function Of 2 Doses Of...” NCT01806896 ↗
11

“Following PF-02545920 In Healthy Subjects” NCT01103726 ↗

NCT00570063 ↗

NCT01829048 ↗

NCT02197130 ↗

NCT02342548 ↗

NCT01939548 ↗

NCT01918202 ↗

NCT01175135 ↗

NCT01806896 ↗

NCT01244880 ↗

NCT00463372 ↗
Known as PF-2545920 ChEMBL registry synonym — accepted as the source's own label CHEMBL562318 ↗
Modality Small molecule — CHEMBL562318 ↗
Route Oral “PF-02545920 administered orally” NCT00463372 ↗
Target PDE10A “This study with PDE10A radioligand [18F]MNI-659 was designed to measure the enzyme occupancy of PF-02545920” PMID 28122201 ↗ Jan 2017